Перейти к содержанию

Abbott Laboratories (ABT) stock: revenue, earnings & dividend

Abbott Laboratories (ABT, NYSE): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener ABT · NYSE Pharma & Biotech US-IL

Key figures

Fiscal year
2025
Revenue
44.3 bn $
Revenue growth
5.7 %
Revenue growth 5y (p.a.)
5.1 %
Net income
6.52 bn $
Net margin
14.7 %
Operating margin
18.2 %
Earnings per share (diluted)
3.72 $
Dividend per share
2.40 $
Payout ratio
64.5 %
Consecutive dividend years
4 years
Consecutive dividend raises
3 years
Dividend growth 5y (p.a.)
–
Total assets
86.7 bn $
Equity
52.1 bn $
Equity ratio
60.1 %
Return on equity
12.5 %
Cash
8.52 bn $
Operating cash flow
9.57 bn $
Free cash flow
7.4 bn $
Shares outstanding
1,731,941,601

History

Revenue by fiscal year

2016 20.9 bn $
2017 27.4 bn $
2018 30.6 bn $
2019 31.9 bn $
2020 34.6 bn $
2021 43.1 bn $
2022 43.7 bn $
2023 40.1 bn $
2024 42 bn $
2025 44.3 bn $

Net income by fiscal year

2016 1.4 bn $
2017 477 m $
2018 2.37 bn $
2019 3.69 bn $
2020 4.5 bn $
2021 7.07 bn $
2022 6.93 bn $
2023 5.72 bn $
2024 13.4 bn $
2025 6.52 bn $

Dividend per share

2022 1.92 $
2023 2.08 $
2024 2.24 $
2025 2.40 $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
202544.3 bn $6.52 bn $3.72 $2.40 $9.57 bn $
202442 bn $13.4 bn $7.64 $2.24 $8.56 bn $
202340.1 bn $5.72 bn $3.26 $2.08 $7.26 bn $
202243.7 bn $6.93 bn $3.91 $1.92 $9.58 bn $
202143.1 bn $7.07 bn $3.94 $–10.5 bn $
202034.6 bn $4.5 bn $2.50 $–7.9 bn $
201931.9 bn $3.69 bn $2.06 $–6.14 bn $
201830.6 bn $2.37 bn $1.33 $–6.3 bn $
201727.4 bn $477 m $0.27 $–5.57 bn $
201620.9 bn $1.4 bn $0.94 $–3.2 bn $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)